Knock-down of ELMO1 in Paediatric Rhabdomyosarcoma Cells by Nanoparticle Mediated siRNA Delivery.

Q1 Engineering

Nanobiomedicine Pub Date : 2016-01-01 DOI:10.5772/62690

Xinyue Huang, Helen Townley

引用次数: 7

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma that is found in children and has a poor outcome for those with metastatic disease. Two histological groups have been distinguished - embryonal (ERMS) and alveolar (ARMS) forms. The ARMS subtype has higher rates of metastasis, as well as higher levels of ELMO1, which is thought to be involved in cell migration. Therefore, the knock-down of ELMO1 by targeted siRNA could provide a mechanism to prevent the metastatic behaviour of ARMS cells. However, challenges still lie in the delivery of nucleotides to a tumour site. Herein, we have described the use of a variety of mesoporous silica nanoparticles as a delivery system for siRNA that is specific for ELMO1 and shown the effective reduction in cell invasive behaviour in these cells.

Abstract Image

查看原文本刊更多论文

纳米颗粒介导的siRNA递送在小儿横纹肌肉瘤细胞中敲除ELMO1

横纹肌肉瘤(Rhabdomyosarcoma, RMS)是儿童中最常见的软组织肉瘤，对于转移性疾病的患者预后较差。两个组织学组已被区分-胚胎(ERMS)和肺泡(ARMS)形式。ARMS亚型具有更高的转移率，以及更高水平的ELMO1，这被认为与细胞迁移有关。因此，靶向siRNA敲除ELMO1可能提供了一种阻止ARMS细胞转移行为的机制。然而，挑战仍然在于将核苷酸运送到肿瘤部位。在本文中，我们描述了使用各种介孔二氧化硅纳米颗粒作为siRNA的递送系统，该系统对ELMO1具有特异性，并显示出有效减少这些细胞中的细胞侵袭行为。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanobiomedicine Biochemistry, Genetics and Molecular Biology-Biotechnology

CiteScore

6.80

自引率

0.00%

发文量

审稿时长

14 weeks

期刊介绍： Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered. All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles. Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to: Nanoscale-structured biomaterials, Nanoscale bio-devices, Nanoscale imaging, Nanoscale drug delivery, Nanobiotechnology, Nanorobotics, Nanotoxicology, Nanoparticles, Nanocarriers, Nanofluidics, Nanosensors (nanowires, nanophotonics), Nanosurgery (dermatology, gastroenterology, ophthalmology, etc), Nanocarriers commercialization of nanobiomedical technologies, Market trends in the nanobiomedicine space, Ethics and regulatory aspects of nanobiomedicine approval, New perspectives of nanobiomedicine in clinical diagnostics, BioMEMS, Nano-coatings, Plasmonics, Nanoscale visualization.